A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer

Indian Journal of Cancer

Volumn 51, Issue 7, 2014, Pages e95-e98

  Wang, T S ^a   Lei, W ^a   Cui, W ^a   Wen, P ^a   Guo, H F ^a   Ding, S G ^a   Yang, Y P ^b   Xu, Y Q ^c   Lv, S W ^c   Zhu, Y L ^c  

^a Women and Infants Hospital of Zhengzhou   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Jinhua City People's Hospital   (China)

Author keywords

Bevacizumab; chemotherapy; meta analysis; ovarian cancer; prognosis; toxicity

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ALBUMINURIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; ENTEROBIASIS; HAZARD RATIO; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; CANCER STAGING; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84926314277     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.154084     Document Type: Article

References (14)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.
4. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: A randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013;31:1719-25.
5. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
6. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
7. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
8. Akers SN, Riebandt G, Miller A, Groman A, Odunsi K, Lele S. Bevacizumab for the treatment of recurrent ovarian cancer: A retrospective cohort study. Eur J Gynaecol Oncol 2013;34:113-9.
9. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-8.
10. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006;102:5-7.
11. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006;107:83-9.
12. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;107:118-23.
13. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
14. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008;111:461-6.